LON:DPH - Dechra Pharmaceuticals PLC (DPH.L) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 3,077.50
  • Forecasted Upside: -10.75 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 3,448
▼ -4 (-0.12%)
1 month | 3 months | 12 months
Get New Dechra Pharmaceuticals PLC (DPH.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 3,077.50
▼ -10.75% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Dechra Pharmaceuticals PLC (DPH.L) in the last 3 months. The average price target is GBX 3,077.50, with a high forecast of GBX 3,515 and a low forecast of GBX 2,510. The average price target represents a -10.75% upside from the last price of GBX 3,448.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Dechra Pharmaceuticals PLC (DPH.L). This rating has held steady since August 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
7/22/2020Jefferies Financial GroupBoost Price TargetBuyGBX 3,185 ➝ GBX 3,515
i
6/5/2020JPMorgan Chase & Co.Lower Price TargetOverweightGBX 3,300 ➝ GBX 3,200
i
6/4/2020Royal Bank of CanadaLower Price TargetSector PerformerGBX 2,560 ➝ GBX 2,510
i
4/24/2020HSBCBoost Price TargetHoldGBX 3,020 ➝ GBX 3,085
i
3/20/2020Royal Bank of CanadaBoost Price TargetSector PerformerGBX 2,530 ➝ GBX 2,560
i
3/13/2020Royal Bank of CanadaBoost Price TargetSector PerformerGBX 2,500 ➝ GBX 2,530
i
2/25/2020JPMorgan Chase & Co.Boost Price TargetOverweightGBX 3,200 ➝ GBX 3,300
i
1/21/2020Jefferies Financial GroupDowngradeHoldGBX 3,090 ➝ GBX 2,930
i
1/6/2020JPMorgan Chase & Co.Lower Price TargetOverweightGBX 3,500 ➝ GBX 3,200
i
12/2/2019HSBCBoost Price TargetHoldGBX 2,915 ➝ GBX 2,950
i
9/4/2019JPMorgan Chase & Co.Boost Price TargetOverweightGBX 3,000 ➝ GBX 3,500
i
9/2/2019Royal Bank of CanadaBoost Price TargetSector PerformGBX 2,100 ➝ GBX 2,500
i
3/25/2019Jefferies Financial GroupBoost Price TargetBuyGBX 2,466 ➝ GBX 2,805
i
3/25/2019JPMorgan Chase & Co.Initiated CoverageOverweightGBX 3,000
i
3/11/2019HSBCLower Price TargetBuyGBX 2,770 ➝ GBX 2,700
i
2/12/2019HSBCInitiated CoverageBuyGBX 2,770
i
11/23/2018Royal Bank of CanadaLower Price TargetSector PerformerGBX 2,400 ➝ GBX 2,100
i
9/3/2018Numis SecuritiesDowngradeHold
i
7/10/2018Numis SecuritiesBoost Price TargetAddGBX 2,640 ➝ GBX 2,950
i
2/26/2018Royal Bank of CanadaReiterated RatingSector performGBX 2,400
i
2/26/2018Numis SecuritiesReiterated RatingAddGBX 2,640
i
2/2/2018Numis SecuritiesReiterated RatingAddGBX 2,640
i
2/1/2018Royal Bank of CanadaDowngradeSector PerformerGBX 2,200 ➝ GBX 2,400
i
1/30/2018Jefferies Financial GroupUpgradeBuyGBX 2,221 ➝ GBX 2,631
i
1/18/2018Numis SecuritiesReiterated RatingAddGBX 2,260
i
1/17/2018Jefferies Financial GroupReiterated RatingHoldGBX 2,221
i
9/5/2017Jefferies Financial GroupBoost Price TargetHoldGBX 1,565 ➝ GBX 1,868
i
7/11/2017Stifel NicolausReiterated RatingHoldGBX 1,550
i
7/6/2017InvestecReiterated RatingBuyGBX 1,840
i
7/6/2017N+1 SingerReiterated RatingBuyGBX 1,666
i
7/6/2017Numis SecuritiesReiterated RatingAddGBX 1,890
i
4/20/2017Panmure GordonReiterated RatingUnder Review
i
4/4/2017Numis SecuritiesBoost Price TargetAddGBX 1,700 ➝ GBX 1,890
i
4/4/2017Stifel NicolausBoost Price TargetHoldGBX 1,440 ➝ GBX 1,550
i
3/14/2017Royal Bank of CanadaBoost Price TargetOutperformGBX 1,630 ➝ GBX 1,890
i
3/1/2017Jefferies Financial GroupBoost Price TargetHoldGBX 1,320 ➝ GBX 1,565
i
2/27/2017N+1 SingerReiterated RatingBuyGBX 1,600
i
2/27/2017Numis SecuritiesReiterated RatingAddGBX 1,700
i
2/24/2017FinnCapReiterated RatingUnder Review
i
1/26/2017Panmure GordonReiterated RatingUnder Review
i
1/17/2017Numis SecuritiesReiterated RatingAddGBX 1,520
i
1/17/2017Panmure GordonReiterated RatingUnder Review
i
12/15/2016Jefferies Financial GroupBoost Price TargetHoldGBX 1,295 ➝ GBX 1,320
i
11/29/2016FinnCapReiterated RatingUnder Review
i
10/27/2016Numis SecuritiesReiterated RatingAddGBX 1,520
i
10/21/2016N+1 SingerBoost Price TargetBuyGBX 1,350 ➝ GBX 1,412
i
10/21/2016Stifel NicolausReiterated RatingHoldGBX 1,250
i
9/16/2016N+1 SingerReiterated RatingBuyGBX 1,350
i
9/11/2016Panmure GordonReiterated RatingBuyGBX 1,140
i
9/9/2016N+1 SingerLower Price TargetBuyGBX 1,350
i
9/7/2016Jefferies Financial GroupBoost Price Target HoldGBX 1,229 ➝ GBX 1,295
i
9/5/2016InvestecBoost Price TargetBuyGBX 1,300 ➝ GBX 1,400
i
9/5/2016Stifel NicolausReiterated RatingHoldGBX 1,250
i
9/5/2016Jefferies Financial GroupReiterated RatingHoldGBX 1,300
i
9/5/2016Panmure GordonReiterated RatingBuyGBX 1,140
i
9/5/2016Numis SecuritiesReiterated RatingAddGBX 1,320
i
8/30/2016FinnCapReiterated RatingUnder Review
i
8/17/2016Numis SecuritiesReiterated RatingAddGBX 1,320
i
7/26/2016Jefferies Financial GroupBoost Price TargetHoldGBX 1,189 ➝ GBX 1,229
i
7/12/2016Numis SecuritiesReiterated RatingAddGBX 1,320
i
6/30/2016Jefferies Financial GroupBoost Price TargetHoldGBX 1,099 ➝ GBX 1,189
i
6/24/2016Numis SecuritiesReiterated RatingAddGBX 1,285
i
6/3/2016Jefferies Financial GroupDowngradeHoldGBX 1,140 ➝ GBX 1,099
i
3/17/2016Numis SecuritiesUpgradeAddGBX 1,285
i
3/17/2016InvestecBoost Price TargetBuyGBX 1,152 ➝ GBX 1,255
i
3/17/2016Royal Bank of CanadaUpgradeOutperformGBX 1,080 ➝ GBX 1,320
i
3/15/2016Numis SecuritiesReiterated RatingHoldGBX 1,095
i
3/15/2016Stifel NicolausReiterated RatingBuyGBX 1,280
i
3/15/2016Panmure GordonReiterated RatingBuyGBX 1,140
i
(Data available from 2/26/2016 forward)
Dechra Pharmaceuticals PLC (DPH.L) logo
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More

Today's Range

Now: GBX 3,448
3,414
3,496

50 Day Range

MA: GBX 3,633.76
3,480
3,802

52 Week Range

Now: GBX 3,448
2,030
3,840

Volume

98,650 shs

Average Volume

202,987 shs

Market Capitalization

£3.73 billion

P/E Ratio

105.12

Dividend Yield

1.02%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dechra Pharmaceuticals PLC (DPH.L)?

The following Wall Street research analysts have issued reports on Dechra Pharmaceuticals PLC (DPH.L) in the last year: HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Royal Bank of Canada.
View the latest analyst ratings for DPH.

What is the current price target for Dechra Pharmaceuticals PLC (DPH.L)?

4 Wall Street analysts have set twelve-month price targets for Dechra Pharmaceuticals PLC (DPH.L) in the last year. Their average twelve-month price target is GBX 3,077.50, suggesting a possible downside of 11.0%. Jefferies Financial Group Inc. has the highest price target set, predicting DPH will reach GBX 3,515 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of GBX 2,510 for Dechra Pharmaceuticals PLC (DPH.L) in the next year.
View the latest price targets for DPH.

What is the current consensus analyst rating for Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L) currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DPH will outperform the market and that investors should add to their positions of Dechra Pharmaceuticals PLC (DPH.L).
View the latest ratings for DPH.

What other companies compete with Dechra Pharmaceuticals PLC (DPH.L)?

How do I contact Dechra Pharmaceuticals PLC (DPH.L)'s investor relations team?

Dechra Pharmaceuticals PLC (DPH.L)'s physical mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company's listed phone number is +44-1606-814730. The official website for Dechra Pharmaceuticals PLC (DPH.L) is www.dechra.com.